SCHEMBL4858644

SCHEMBL4858644

CSc1ccc(C(=N)Nc2ccc(C)c(C)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.51
NPC1 O15118 5/20 0.51
MAPT P10636 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
KMT2A Q03164 4/20 0.44
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.43
BLM P54132 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
KDM4E B2RXH2 1/20 0.42
F13A1 P00488 1/20 0.41
TGM2 P21980 1/20 0.41
GAA P10253 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14193769 0.82 NPC1 (0.47) RAB9ANPC1MAPTCYP1A2CYP2C19
SCHEMBL4853065 0.82 NPC1 (0.47) RAB9ANPC1MAPTCYP1A2CYP2C19
SCHEMBL4862311 0.80 RAB9A (0.61) RAB9ANPC1MAPTCYP1A2CYP3A4
SCHEMBL4852963 0.78 IDO1 (0.44) MAPTCYP1A2CYP3A4CYP2C19KMT2A
SCHEMBL4856115 0.78 MEN1 (0.49) RAB9ANPC1MAPTCYP1A2CYP3A4
SCHEMBL4857030 0.78 ALDH1A1 (0.46) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL4854757 0.78 ALDH1A1 (0.46) RAB9ANPC1MAPTCYP1A2CYP2C9
SCHEMBL4864119 0.78 MEN1 (0.49) RAB9ANPC1MAPTCYP1A2CYP3A4
SCHEMBL4857004 0.77 MAPT (0.49) RAB9ANPC1MAPTCYP1A2CYP3A4
SCHEMBL4861618 0.76 KDM4E (0.43) RAB9ANPC1MAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP RAB9A 2079/4885NPC1 1563/4885MAPT 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.